New practical definitions for the diagnosis of autosomal recessive spastic ataxia of Charlevoix–Saguenay

Autosomal recessive spastic ataxia of Charlevoix–Saguenay (ARSACS) is caused by mutations in the SACS gene. SACS encodes sacsin, a protein whose function remains unknown, despite the description of numerous protein domains and the recent focus on its potential role in the regulation of mitochondrial physiology. This study aimed to identify new mutations in a large population of ataxic patients and to functionally analyze their cellular effects in the mitochondrial compartment.

[1]  E. Leshinsky‐Silver,et al.  Molecular and functional studies of retinal degeneration as a clinical presentation of SACS-related disorder. , 2015, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[2]  L. Wilkins.  SPG7 mutations are a common cause of undiagnosed ataxia , 2015, Neurology.

[3]  E. Shoubridge,et al.  Sacs knockout mice present pathophysiological defects underlying autosomal recessive spastic ataxia of Charlevoix-Saguenay. , 2015, Human molecular genetics.

[4]  P. Chinnery,et al.  Disturbed mitochondrial dynamics and neurodegenerative disorders , 2015, Nature Reviews Neurology.

[5]  E. Rugarli,et al.  Loss of the m‐AAA protease subunit AFG3L2 causes mitochondrial transport defects and tau hyperphosphorylation , 2014, The EMBO journal.

[6]  D. G. MacArthur,et al.  Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.

[7]  Robert W. Taylor,et al.  Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance , 2014, Brain : a journal of neurology.

[8]  P. Chinnery,et al.  Abnormal retinal thickening is a common feature among patients with ARSACS-related phenotypes , 2014, British Journal of Ophthalmology.

[9]  A. Deshpande,et al.  Case report of autosomal recessive spastic ataxia of Charlevoix-Saguenay , 2014 .

[10]  B. Gilbert-Dussardier,et al.  High‐resolution array‐CGH in patients with oculocutaneous albinism identifies new deletions of the TYR, OCA2, and SLC45A2 genes and a complex rearrangement of the OCA2 gene , 2014, Pigment cell & melanoma research.

[11]  J. Bouchard,et al.  Clinical presentation and early evolution of spastic ataxia of Charlevoix‐Saguenay , 2013, Movement disorders : official journal of the Movement Disorder Society.

[12]  L. Pablo,et al.  Retinal segmentation as noninvasive technique to demonstrate hyperplasia in ataxia of Charlevoix-Saguenay. , 2013, Investigative ophthalmology & visual science.

[13]  B. Bender,et al.  Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum , 2013, Orphanet Journal of Rare Diseases.

[14]  F. Cavalcanti,et al.  Sacsin-Related Spastic Ataxia Caused by a Novel Missense Mutation p.Arg272His in a Patient from Sicily, Southern Italy , 2013, The Cerebellum.

[15]  L. Minati,et al.  Supratentorial and pontine MRI abnormalities characterize recessive spastic ataxia of Charlevoix‐Saguenay. A comprehensive study of an Italian series , 2013, European journal of neurology.

[16]  A. Montpetit,et al.  Diversity of ARSACS Mutations in French-Canadians , 2013, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[17]  A. Tessa,et al.  Comparative Analysis and Functional Mapping of SACS Mutations Reveal Novel Insights into Sacsin Repeated Architecture , 2012, Human mutation.

[18]  G. Gyapay,et al.  Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia. , 2012, American journal of human genetics.

[19]  E. Shoubridge,et al.  Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) , 2012, Proceedings of the National Academy of Sciences.

[20]  A. Durr,et al.  REEP1 mutations in SPG31: Frequency, mutational spectrum, and potential association with mitochondrial morpho‐functional dysfunction , 2011, Human mutation.

[21]  V. Narayanan,et al.  Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay , 2011, Journal of child neurology.

[22]  F. Hentati,et al.  Autosomal recessive spastic ataxia of Charlevoix-Saguenay: an overview. , 2011, Parkinsonism & related disorders.

[23]  B. Chazotte.  Labeling mitochondria with TMRM or TMRE. , 2011, Cold Spring Harbor protocols.

[24]  B. Brais,et al.  Structural Basis of Defects in the Sacsin HEPN Domain Responsible for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)* , 2011, The Journal of Biological Chemistry.

[25]  W. Robberecht,et al.  Mutations in SACS cause atypical and late-onset forms of ARSACS , 2010, Neurology.

[26]  Efraín Siller,et al.  The sacsin repeating region (SRR): a novel Hsp90-related supra-domain associated with neurodegeneration. , 2010, Journal of molecular biology.

[27]  D. Guernsey,et al.  Novel mutations in the sacsin gene in ataxia patients from Maritime Canada , 2010, Journal of the Neurological Sciences.

[28]  N. Drouot,et al.  Molecular diagnosis of known recessive ataxias by homozygosity mapping with SNP arrays , 2010, Journal of Neurology.

[29]  T. Webb,et al.  The ataxia protein sacsin is a functional co-chaperone that protects against polyglutamine-expanded ataxin-1 , 2009, Human molecular genetics.

[30]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[31]  J. Cruysberg,et al.  ARSACS in the Dutch population: a frequent cause of early-onset cerebellar ataxia , 2008, neurogenetics.

[32]  S. Sookoian,et al.  A Decreased Mitochondrial DNA Content Is Related to Insulin Resistance in Adolescents , 2008, Obesity.

[33]  N. Janin,et al.  Novel SACS mutation in a Belgian family with sacsin-related ataxia , 2008, Journal of the Neurological Sciences.

[34]  F. Hentati,et al.  Autosomal Recessive Ataxia Caused by Three Distinct Gene Defects in a Single Consanguineous Family , 2008, Journal of neurogenetics.

[35]  M. Sylvain,et al.  Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: A Report of MR Imaging in 5 Patients , 2007, American Journal of Neuroradiology.

[36]  M. Nishizawa,et al.  Sacsin‐related ataxia with neither retinal hypermyelination nor spasticity , 2007, Movement Disorders.

[37]  J. Estaquier,et al.  Inhibiting Drp1-mediated mitochondrial fission selectively prevents the release of cytochrome c during apoptosis , 2007, Cell Death and Differentiation.

[38]  C. Espinós,et al.  Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .

[39]  Y. Takiyama.  Autosomal recessive spastic ataxia of Charlevoix‐Saguenay , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.

[40]  S. Sakoda,et al.  Novel compound heterozygous mutations in sacsin-related ataxia , 2005, Journal of the Neurological Sciences.

[41]  S. Frank,et al.  The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. , 2001, Developmental cell.

[42]  E. Lander,et al.  ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORF , 2000, Nature Genetics.

[43]  G. Bruyn,et al.  Hereditary neuropathies and spinocerebellar atrophies , 1991 .